Enbrel, an FDA approved drug, is linked to several serious adverse effects, some that are even fatal, including risk of cancer.

Enbrel is an arthritis injectable medication sold in the market under the name etanercept. It is approved to treat several types of arthritis including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and idiopathic arthritis. The drug has been around since the 90’s and has been widely prescribed.

Enbrel is a genetically made Tumor Necrosis Factor blocker, coming from a natural substance from the body, which is made during the body’s auto-immune response. For some cases of arthritis, Tumor Necrosis Factor (TNF) is in the blood and joints. Excessive amount of TNF heightens pain and swelling. Etanercept works by decreasing TNF in the body’s immune system, easing the inflammation.

The use of Enbrel already comes with health warnings. As the manufacturer precaution says: Serious infections have happened in patients taking ENBREL.These infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some patients have died from these infections.

Have you been injured by a Dangerous Drug or Recalled Medical Device?
If you or a loved one was injured by Dangerous Drug or Recalled Medical Device, you may be entitled to compensation.

Aside from those already-warned adverse effects, Enbrel is also allegedly linked to the risk of cancer. This fatal condition is among the reasons why Enbrel has been under the scrutiny of many lawyers and are bombarded with lawsuits filed by Plaintiffs.

Enbrel is also linked to bone fractures, which may include:

  • bruising, swelling and redness over the area affected
  • extreme pain when the bone is moving
  • the bone may came out of the body

Patients who are injured by Enbrel‘s adverse effects are encouraged to seek advice from a lawyer about their legal options. They may be able to get compensation just like those Plaintiffs who filed cases against the manufacturer of the drug.